Immune reset: CAR-T therapy targets lupus and other autoimmune conditions
NCT ID NCT06548607
First seen Mar 18, 2026 · Last updated Jun 16, 2026 · Updated 17 times
Summary
This early-stage study is testing a new treatment using a patient's own immune cells, modified to target and attack faulty immune cells that cause autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. The goal is to see if this approach is safe and can control disease activity. The study involves 20 adults aged 18 to 70 with active disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Third the People's Hospital of Bengbu
RECRUITINGBengbu, Anhui, 233000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.